Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study-Reference-Cited by-同舟云学术

Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study

Published:2023-04 Issue:4 Volume:11 Page:354-366
ISSN:2213-2600
Container-title:The Lancet Respiratory Medicine
language:en
Short-container-title:The Lancet Respiratory Medicine

Author:

Solomon Benjamin J,Bauer Todd M,Mok Tony S K,Liu Geoffrey,Mazieres Julien,de Marinis Filippo,Goto Yasushi,Kim Dong-Wan,Wu Yi-Long,Jassem Jacek,López Froylán López,Soo Ross A,Shaw Alice T,Polli Anna,Messina Rossella,Iadeluca Laura,Toffalorio Francesca,Felip Enriqueta

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine

Reference22 articles.

1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J Clin,2021

2. The effect of advances in lung-cancer treatment on population mortality;Howlader;N Engl J Med,2020

3. Update 2020: management of non-small cell lung cancer;Alexander;Lung,2020

4. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer;Soda;Nature,2007

5. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer;Koivunen;Clin Cancer Res,2008

Cited by 96 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Central nervous system metastases in advanced non-small cell lung cancer: A review of the therapeutic landscape;Cancer Treatment Reviews;2024-11

2. New findings on the incidence and management of CNS adverse reactions in ALK-positive NSCLC with lorlatinib treatment;Discover Oncology;2024-09-13

3. Harnessing the potential of genomic characterization of mutational profiles to improve early diagnosis of lung cancer;Expert Review of Molecular Diagnostics;2024-09-12

4. New Benchmark for Targeted Therapies in Lung Cancer: Median Progression-Free Survival for Lorlatinib in Advanced ALK+ Non–Small Cell Lung Cancer Surpasses 5 years;Journal of Clinical Oncology;2024-09-04

5. Spatial Immunogenomic Patterns Associated with Lymph Node Metastasis in Lung Adenocarcinoma;2024-09-03